CAS: 39944-62-2; Pyrimidine-2,4,5,6-Tetraamine Hydrochloride(1:X)

相似化合物

5392-28-9 118-70-7 13754-19-3

上下游产品

CAS号5392-28-9 2,4,5,6-四氨基嘧啶硫酸盐 | CAS号945-24-4 2,4-二氨基-6-羟甲基蝶啶 | CAS号30146-32-8 2,4-Pteridinedi... | CAS号1029-87-4 Pteridine, 2,4-... | CAS号708-74-7 2,4-Pteridinedi... | CAS号7761-75-3 呋氨蝶啶

专利信息

专利号:WO-2013164856-A1
优先权日:2012-05-04
标题 :A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
发明人：ALLA RAMA RAO VENKATA; RAMARAO CHANDRASHEKAR; MICHEL PATRICK THOMAS; NITLIKAR LAKSHMIKANT HANUMANTHRAO; KALAM BHUPATHI REDDY; DUDUKA RAMPRASAD
权利人:AVRA LAB PRIVATE LTD; ALLA RAMA RAO VENKATA; RAMARAO CHANDRASHEKAR; MICHEL PATRICK THOMAS; NITLIKAR LAKSHMIKANT HANUMANTHRAO; KALAM BHUPATHI REDDY; DUDUKA RAMPRASAD
摘要:A process for preparation of 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid and other key intermediates in synthesis of 10-propargyl-10-deazaaminopterin (Pralatrexate) and the intermediates thereof. The 10-propargyl-10-deazaaminopterin (Pralatrexate) is obtained by peptide formation and ester hydrolysis of the intermediate compound 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid by methods known in the art.

专利号:US-4167633-A
优先权日:1977-07-20
标题 :Preparation of 2,4,5,6-tetraaminopyrimidine from 2,4,6-triaminopyrimidine
发明人：MORROW THOMAS J
权利人:US HEALTH EDUCATION & WELFARE
摘要:An improved process for the production of ##STR1## FROM ##STR2## WHICH PRODUCES BUT DOES NOT ISOLATE AN INTERMEDIATE ##STR3## WHICH COMPOUND IS RETAINED IN SITU AND MINIMIZES THE COMPLEX POLYMER FORM OF A THREE-DIMENSIONAL NETWORK OF AZO LINKAGES FORMED BY THE NITROSO AND AMINO GROUPS. These groups, as they appear in the nitroso intermediate, have carcinogenic possibilities. It has been found that the nitroso compound will precipitate as a stirrable slurry if the temperature parameter is kept low at about 0°-20° C. A preferred route for the production of the nitroso compound from the triamino starting material utilizes as reactants 1.0-1.05 moles of sodium nitrite and 1.5 moles of HOAc in water (HCl may be substituted for HOAc). In the second state of this sequential reaction, the reduction of nitroso is carried out by a reducing agent and one preferred agent is sodium dithionite. Catalytic agents such as Raney nickel and hydrazine or nickel salts, e.g., nickel chloride, and sodium borohydride may also be used. The present process is an improvement in part of the technique of Piper and Montgomery, J. Het. Chem., 11:279 (1974), which process is designed specially to produce the antifolate methotrexate as an end product and is an improvement of the method of application Ser. No. 742,450 of Ellard filed Nov. 17, 1976, entitled 'Improved Synthesis of Methotrexate', U.S. Pat. No. 4,080,825.

专利号:US-4080325-A
优先权日:1976-11-17
标 题 :Synthesis of methotrexate
发明人：ELLARD JAMES A
权利人:US HEALTH EDUCATION & WELFARE
摘要:The present invention consists of three process improvements in the so-called multi-step Piper-Montgomery process designed especially to produce the antifolate methotrexate which is closely related to both aminopterin and folic acid. 2,4,5,6-tetraaminopyrimidine sulfite is one starting material and is usually produced in the form of the bisulfite in an acetate buffer. The present modification positively produces the hydrochloride from the bisulfite and eliminates the acetate buffer utilized in prior art processes. Subsequently, a pteridine ring is formed from the pyrimidine hydrochloride using dihydroxyacetone at pH 5.5±0.2 to form the second ring. This strict pH control together with the use of hydrochloride salt minus the acetate buffer assists in preferentially favoring the formation of 2,4-diamino-6-hydroxymethylpteridine. Subsequently the 6-hydroxy-methyl compound is converted to the hydrobromide acid salt and reacted with three moles of a triphenyl dibromophosphorane and phosphazine protecting groups are formed on the amine groups of the pteridine ring as the 6-hydroxymethyl group is transformed to 6-bromomethyl, a key intermediate. The present process leaves the protecting phosphazine groups on the primary amino groups to discourage side reactions during subsequent alkylation of the other major reactant, ethyl N-(p-methylaminobenzoyl)-L-glutamate. Furthermore, ethyl N-(p-methylaminobenzoyl)-L-glutamate, the other reactant, is uniquely produced for the present multi-step reaction by a process proceeding from ethyl N-(p-trifluoromethylaminobenzoyl)-L-glutamate by utilizing an alkali metal hydroxide in a lower (C 1 -C 6 ) alkanol wherein the protective trifluoroacetyl groups are removed. This step uses a special mixture preferably of an alkali metal hydroxide in ethanol and optimally 1 equivalent of KOH in 20% ethanol at or below ambient temperature where the mixture is added slowly to keep the reaction pH below 9. The combination of these improvements results in the increase of an overall yield of methotrexate from the named starting reactants from about 25% to approximately 40-50%.

专利号:CA-1077477-A
优先权日:1976-11-17
标题:Synthesis of methotrexate

专利号:GB-1595338-A
优先权日:1976-11-17
标题:Synthesis of 2,4-diamino-6-hydroxymethyl-pteridine

专利号:GB-1595337-A
优先权日:1976-11-17
标题:Synthesis of methotrexate